Cardiac hypertrophy is a complex and non-homogenous response to various stimuli. In this study, we used high-density oligonucleotide microarray to examine gene expression profiles during physiologic hypertrophy, pathologic hypertrophy, and heart failure in Dahl salt-sensitive rats. There were changes in 404/3160 and 874/3160 genes between physiologic vs. pathologic hypertrophy and the transition from hypertrophy to heart failure, respectively. There were increases in stress response genes (e.g. heat shock proteins) and inflammation-related genes (e.g. PAP and Alox12) in pathologic processes but not in physiologic hypertrophy. Furthermore, atrial natriuretic factor (ANF) and brain natriuretic protein (BNP) showed distinctive changes that are very specific to different conditions. In addition, we used resampling-based gene score calculating method to define significantly altered gene clusters based on Gene Ontology (GO) classification. It revealed significant alterations in genes involved in the apoptosis pathway during pathologic hypertrophy suggesting that the apoptosis pathway may play a role during the transition to heart failure. In addition, there were significant changes in glucose/insulin signaling, protein biosynthesis and epidermal growth factor signaling during physiologic hypertrophy, but not during pathologic hypertrophy.
Note: All abbreviations in the manuscript are listed in Table 1 .
Introduction
Cardiac hypertrophy is a complex response to various hypertrophic signals that promote the growth of cardiac myocytes. Multiple neurohumoral, hormonal and mechanistic stimuli have been implicated in, and numerous interdependent pathways and molecules shown to be associated with, cardiac hypertrophy (10, 37) . Accordingly, the responses of cardiac myocytes to different hypertrophic stimuli are not homogenous.
Examples of stimulus-dependent hypertrophic response can be found in both physiologic and pathologic hypertrophy. Exercise-induced cardiac hypertrophy is a good example of physiologic hypertrophy, which is a favorable adaptive response of the heart to increases in bodily demand (8) . In comparison, pathologic hypertrophy is a maladaptive response to pathologic stimuli, such as pressure or volume overload. These differences are particularly evident clinically, for pathologic hypertrophy often progresses to heart failure, especially when pathologic stimuli are persistent, whereas physiologic hypertrophy usually does not. These examples support the notion that cardiac hypertrophies are not all the same, and suggest that stimulus specific hypertrophic responses may be associated with distinct molecular changes (20,27).
Previous studies of models of cardiac hypertrophy using microarray technology have yielded interesting but varied results (1, 4, 13, 16, 19, 23, 31, 32, 34, 50, 54) . Studies of putative physiologic stimuli showed increased expression of genes involved in the cell cycle, cell structure, intracellular signaling, protein synthesis, and metabolism (13, 16, 31, 34) . Pathologic stimuli, however, such as in the experimental animal 4 myocardial infarction models, are associated with the increased expression of genes involved in inflammation, wound healing, structural proteins, metabolism and survival (23, 32, 50) . However, different transgenic mouse models of cardiac hypertrophy revealed no consistent change in any single gene, although there was a correlation between the number of differentially expressed genes and the degree of hypertrophy (1) .
In this study, we used rat models of physiologic hypertrophy and pathologic hypertrophy that progresses to heart failure in the Dahl salt-sensitive (DS) rat (25) . Using microarray analysis, we examined differences in gene expression in physiologic and pathologic hypertrophy, and how the pattern of gene expression changes during the transition from hypertrophy to heart failure.
Materials and Methods
Exercise-and High Salt Diet-induced Cardiac Hypertrophy.
Physiologic and pathologic rat models of cardiac hypertrophy and heart failure were created as previously described (25). Briefly, physiologic cardiac hypertrophy was generated by a vigorous daily exercise regimen for 6 weeks. Pathological cardiac hypertrophy was generated by feeding a 6% NaCl diet for 6 weeks. With continued high salt diet, these rats developed clinical heart failure after 15-18 weeks. Control rats were sedentary and age matched DS rats fed normal rat chow.
Echocardiography
Rats were anesthetized with an intraperitoneal injection of ketamine HCl (50 mg/kg) and xylazine (10 mg/kg). Echocardiography was performed in prone 5 decubitus position with a Hewlett-Packard Sonos 1500 sector scanner equipped with a 7.5 MHz phased-array transducer. Two-dimensionally guided M-mode tracings were recorded on strip-chart paper at a paper speed of 100 mm/s. Anterior and posterior wall thickness and LV internal dimensions were measured according to the leading-edge method of the American Society of Echocardiography.
RNA isolation and Northern analysis
Total RNA from ventricles was isolated as previously described (34) . Briefly, the hearts were rapidly removed and the atria and right ventricles were cut and snap frozen in liquid nitrogen. Total RNA was isolated using the TRIzol Reagent (Life Technologies) following the instructions of the manufacturer. Isolated RNA was further purified by a phenol-chloroform extraction, followed by ethanol precipitation. Northern analysis was performed according to the published protocol (48) . The probes for mouse ANF, mouse BNP and rat GAPDH probes were prepared as previously described (34) .
Microarray analysis and statistics
This study was conducted in collaboration with the NHLBI-sponsored Program in Genomic Application (PGA), and was performed with strict quality assurance set by the PGA. The details of the methods could be found at CardioGenomics website (http://www.cardiogenomics.org). Generation of biotinylated cRNA probe for the Affymetrix arrays was performed according to Affymetrix's protocols. Affymetrix oligonucleotides Rat Genome U34A GeneChips (Affymetrix, Santa Clara, CA), which contain 8,799 probe sets for known genes and expressed sequence tags (ESTs), were used 6 in our study. Normalization was done using invariant set normalization algorithms with dChip v 1.3 and PM/MM difference model based expression index (MBEI) were calculated (30) . To identify the presence of transcripts, Affymetrix Microarray Suite (MAS version 5.01) was used. All genes identified as "absent" in all 24 arrays, and control probe sets were excluded. We found 3944 genes (44.82%) were designated "absent" across all 24 arrays and 59 control probe sets. Probe sets from the same UniGene clusters (build #131 as of Apr. 2004) were averaged. This process reduced the available transcripts number further to 3160 from 8799. The remaining 3160 genes were then statistically filtered for detecting significantly differently expressed genes across the experimental conditions. First, statistical filtering with two-way ANOVA was done as shown in Figure 1 .
To assess the profiles of gene expression changes between physiological and pathological hypertrophy, we compared 3 groups at two time points i.e., 3 weeks and 6 weeks ( Figure   1A ). High salt diet models of 3 time points were compared with control groups of the same ages ( Figure 1B ) to evaluate the transition of pathological hypertrophy to heart failure. Then q-value was used to assess the false discovery rates with two-way ANOVA p-values (44, 51) . Significant genes from two-way ANOVA were exported to Spotfire DecisionSite 7.3 software (Spotfire, Sommerville, MA), where K-means cluster analysis was done.
Second, we compared each experiment condition at different time points to age matched control group with Welch's t-test. Venn diagram was created with genes, which showed minimum lower confidence bound of 1.5 fold in each comparison using dChip software. The p-values of statistical comparison were exported to ErmineJ software 7 (http://microarray.genomecenter.columbia.edu/ermineJ) to identify enriched Gene Ontology (GO) classes. We used GO classes of size k=5 to 250. To test the significance of each class, we draw a random set of genes of same size from the data and calculate the raw score r = -Σ j log (p j ) where p j is the p-value for each gene in the random sample. This procedure was done 200,000 times to calculate the distribution of raw score r under the null hypothesis. The overall significance for a class with a raw score r is calculated as the fraction of random trials resulting in a score higher than r (45) .
Results

Animal models
Both exercise (EX) and high salt diet (HS) induced significant cardiac hypertrophy in DS rats compared to the control (Table 2 ). Hearts from both the EX group and the HS group showed significant increases in wall thickness by echocardiogram. The body and tissue weights of EX and HS rats showed significant increases in heart weight without changes in other tissue weights. These findings were consistent with cardiac hypertrophy with preserved cardiac function. Continuation of high salt diet in the HS group resulted in clinical heart failure and death ( Figure 1C ).
These rat hearts showed significant increases in wall thickness, LV chamber diameter, and a decrease in fractional shortening consistent with hypertensive dilated cardiomyopathy ( Table 2 ). There were significant decreases in body weight due to cardiac cachexia, a nearly two-fold increase in heart weight, and significant increases in the lung and liver weights consistent with left-and right-sided heart failure, respectively.
Genetic Profiles of Physiologic and Pathologic Cardiac Hypertrophy
Among 3160 genes analyzed in HS and EX at 3 and 6 weeks, 404 genes showed changes that were statistically significant at model q-value < 0.05. K-means clustering (k = 6) showed distinctive clustering for the control, physiologic hypertrophy and pathologic hypertrophy at 6 weeks of stimuli ( Figure 2A ). Most of the significant changes occurred after 6 weeks of stimuli in HS and EX suggesting that majority of molecular changes occurred when there were significant phenotypic changes. Many of the genes were predominately altered in pathologic hypertrophy but not in physiologic hypertrophy (154/404)(Cluster 1 and 2). These included ANF, BNP, and GATA4, which are known to change during cardiac hypertrophy. Of note, these clusters include SOD2, ICAM1, HAND2, presenilin 1 and von Willebrand factor, which known to be upregulated during oxidative stress. This finding suggests that pathological stimulus invokes the oxidative stress response, but physiologic hypertrophy does not. A significant number of genes were changed in both physiologic and pathologic hypertrophy (159/404) (Cluster 5 and 6). This group of genes is comprised of known hypertrophic response proteins, such as MAP kinase 6 and 12, PECAM1, UCP2, phospholamban, Grb2, and GSK3β, suggesting that these genes are associated with both pathologic and physiologic hypertrophy. Only 91/404 genes were changed predominately in physiologic hypertrophy (Cluster 3 and 4). Genes in this group were predominately involved in metabolism and cell growth; further supporting the notion that physiologic hypertrophy is associated with normal growth of the heart to keep up with the increased demand of the heart. ADRBK1 and MMP14 are in these clusters. Venn 9 diagram analysis at 6 weeks demonstrated that most of the gene changes occurred either only during physiologic hypertrophy (74 genes) or only during pathologic hypertrophy (120 genes) suggesting that conditions are characterized by distinct gene expressions ( Figure 2B ). There were 50 genes that showed changes in both conditions. Genetic Profiles of Pathologic Cardiac hypertrophy and Heart Failure Genetic changes that are associated with the transition from compensated cardiac hypertrophy to decompensated heart failure showed 874/3160 genes that were changed with a statistical significance of model q-value <0.05. K-mean clustering into six distinct patterns revealed that most of the genes (369/874 genes) were changed in both hypertrophy and heart failure (Cluster 5 and 6) ( Figure 2C ). These genes included hypertrophic signaling genes, such as GATA4, RAB7, NRAS, GNA12, STAT3, STAT5B, FYN, CRKO, MYCN, PTEN, AKT1, and IL6ST/gp130. These findings suggest that these pathways are significantly activated during the transition from compensated pathologic hypertrophy to decompensated heart failure. There were also several genes that encode for channels, such as VDAC1 and CAVNβ2 that suggest the possible role of these channel proteins in the process. There were 205/874 genes altered predominantly in hypertrophy (Cluster 3 and 4) and 300/874 genes altered predominately in heart failure (Cluster 1 and 2). These included genes associated with oxygen regulation and deprivation, such as heme oxygenase-1, HAGH, thioreductase 2, SOD2, cytochrome b5, suggesting oxygen deprivation is an important aspect of pathologic hypertrophy and heart failure. Furthermore, several stress reactive genes, such as heat shock proteins (hsp) (hsp 40, 70), and inflammation related genes, such as Alox12, PAP, were upregulated in these groups. The fold changes of all the significant genes were described in Supplement Table 1 . Venn diagram analysis revealed that most of the gene changes occurred in H6 (120 genes) and H15 groups (89 genes) when there were obvious phenotypic changes ( Figure 2D) . ANF was the only gene that changes in all three pathologic groups, but not in physiologic groups ( Figure 2D and Figure 3 ).
Specific Genes of Interests ANF and BNP have been shown to be upregulated during hypertrophy and heart failure (3, 26, 28, 29, 33, 49) . In our study, there was significant upregulation of ANF mRNA expression in pathologic hypertrophy (6.1-fold) and even greater increase in heart failure (14.3-fold) ( Figure 3A and 3B). ANF was also increased in physiologic hypertrophy (2.3-fold), although significantly less in comparison to pathologic conditions. There was significant increase in tissue mRNA BNP level during pathologic hypertrophy (3.0-fold), but not physiologic hypertrophy. Interestingly, there was significant down regulation of tissue mRNA BNP level during the transition to decompensated heart failure to the baseline level ( Figure 3A and 3B). Since these two genes show very distinctive change patterns during hypertrophic/heart failure, the absolute levels as well the ANF/BNP ratio may be a useful in understanding the current therapeutic strategy for the treatment of decompensated heart failure.
A significant difference between pathologic and physiologic hypertrophy was the change in acute stress reactants and inflammatory related genes in pathologic hypertrophy. Pathologic hypertrophy resulted in up-regulation of 84 genes, compared to 19 genes in physiologic hypertrophy (see Supplemental Table 1 ). In addition, the state of decompensated heart failure resulted in an even more impressive activation of stress reactants. Moreover, there was extremely high activation of inflammatory response genes, such as PAP (123-fold), Alox-12 (25-fold), during heart failure ( Figure 3C ).
These findings suggest a potentially important role of inflammation during the transition from compensated hypertrophy to decompensated heart failure.
Hypertrophic signaling pathways
To identify group of genes that are altered during various stimuli, we used resampling-based gene score calculating method to define significantly altered gene clusters based on GO classification. During pathologic hypertrophy, genes associated with apoptosis pathway showed statistically significant change. Analysis of genes classified as apoptosis genes revealed that during pathologic hypertrophy, there was highly statistically significant change in these genes (Table 3) . Genes associated with regulation of apoptosis, apoptosis inhibitor activity, anti-apoptosis, regulation of apoptosis and regulation of programmed cell death showed statistical changes during pathologic hypertrophy. Interestingly, only apoptosis inhibitor activity and anti-apoptosis showed statistically significant changes during physiologic hypertrophy (Table 3 ). This finding suggests that there is increased apoptotic modulation during pathologic hypertrophy that may play a role during the transition from pathologic hypertrophy to heart failure.
In comparison, we identified several signaling pathways that were statistically changed only during physiologic hypertrophy (Table 3) . For example, the gene clusters associated with glucose/insulin signaling, protein biosynthesis and epidermal growth factor (EGF) signaling showed statistically significance changes during physiologic hypertrophy, suggesting that these pathways may be involved predominately during physiologic hypertrophy. Interestingly, EGF signaling activation occurred only early during physiologic hypertrophy (i.e. E3 group). Complete list of enriched GO classes are described in Supplement Table 2 .
Discussion
In this study, we analyzed gene expression in two distinct models representative of physiologic and pathologic cardiac hypertrophy. Despite developing a comparable degree of hypertrophy, there were significant differences in molecular changes associated with specific stimuli, suggesting that different genetic programs may be altered in the two models. Specific changes occurred in a wide range of genes involved in hypertrophic signaling, metabolism, cell structural organization, cell death, stress responses, and ion channels that may be important in understanding the pathophysiology of these conditions. Since pathologic hypertrophy usually progresses to heart failure, a better characterization of the changes seen in pathologic compared to physiologic hypertrophy may provide clues to the specific pathways involved in the progression to heart failure.
Our findings suggest that pathologic processes, such as pathologic hypertrophy and heart failure, are characterized by an increase in the stress genes, such as genes involved in inflammation, oxidative stress and acute stress response. Physiologic hypertrophy did not manifest these changes in stress genes. Also, our data is consistent with previous findings that PAP and Alox12 increase significantly during the transition to heart failure in Dahl rats (54) . PAP is a 16 kDa secretory protein belonging to the C-type 13 lectin family (14) that is strongly up-regulated by pro-inflammatory mediators, such as the cytokines IL6 (6). PAP is speculated to be involved in cell proliferation (39) , the inhibition of apoptosis (12, 42, 43) , and anti-inflammatory function (18,55). Alox12 is a member of a family of lipoxygenases that metabolize arachidonic acid (5). Alox12 activation may play a role in Ang II-induced vascular smooth muscle cell hypertrophy (41) . Furthermore, mice deficient in the leukocyte-type 12-lipoxygenase have impaired protection after ischemic preconditioning, suggesting that leukocyte 12-lipoxygenase is an important mediator of preconditioning (17).
The transition from pathologic hypertrophy to heart failure has been shown to involve cardiac apoptosis in various human and animal models of heart failure (24). In this study, we found that various components of apoptosis pathways were significantly changed during pathologic processes, particularly during pathologic hypertrophy.
Previously, we demonstrated that a pro-apoptotic milieu is induced during pathologic hypertrophy that may cause cardiac myocytes to be more sensitive to apoptotic stimuli (25). In addition, in microarray analysis of various transgenic mice that are associated with hypertrophy and heart failure, the Gαq transgenic mouse heart revealed an increased expression of apoptosis genes (1). This finding suggests that the apoptosis pathway may be associated with significant changes during pathologic hypertrophy and may contribute to the development of heart failure in this model. In our study, there was a significant change in several signaling pathways during physiologic hypertrophy. The insulin pathway plays an important role in normal growth and development in various tissues (7) . It is also a major regulator of insulin-like growth factor-1 (IGF-1)/phosphatidylinositol 3-kinase (PI3K), which in turn regulates many important biological responses, such as cell growth and survival (9, 53) . In the heart, the IGF and PI3K pathway has been implicated in normal cardiac growth and the development of physiologic hypertrophy (34, 35, 48) . Overexpression of IGF receptor 1 induces compensated cardiac hypertrophy resembling physiologic hypertrophy in a PI3K pathway-dependent manner (34) . Furthermore, cardiac specific overexpression of dominant negative PI3K is associated with hypertrophy in response to pressure overload via aortic banding, but not to exercise-induce cardiac hypertrophy (35) . In fact, mTOR/S6K/E1BP pathway that is downstream of PI3K pathway has been shown to be important for protein biosynthesis during physiologic hypertrophy (15, 38, 47) . Our current data is consistent with our previous findings in mouse models that suggest that the insulin/IGF/PI3K pathway axis plays a dominant role in physiologic hypertrophy.
Furthermore, our data suggest that other pathways, such as EGF pathway, might be involved in physiologic hypertrophy. EGF pathway has been shown to cause hypertrophy via shedding of EGF by metalloproteinase ADAM12 or via cyclic AMP stimulation (2, 40) .
ANF and BNP are a family of structurally related peptides that participate in the integrated control of renal and cardiovascular function. ANF is mainly secreted by the atria in response to the stretch that occurs with the increased left-atrial pressure associated with CHF. Its level is known to rise early in the course of heart failure and has been used as a marker for the diagnosis of asymptomatic, left ventricular dysfunction with a sensitivity and specificity of more than 90% (29). BNP is synthesized predominantly in ventricular myocardium in response to increased wall stress, hypertrophy and volume overload (26). The plasma concentrations of both ANF and BNP are increased in patients with either asymptomatic or symptomatic left ventricular dysfunction, permitting their use in diagnosis as well as providing prognostic information in patients with chronic CHF, including those receiving therapy with a β-blocker and an ACE inhibitor (3,28,33,49 ). In addition, Nesiritide ® (recombinant human BNP) produces significant improvement in various hemodynamic parameters and shown to be effective therapy in the treatment of decompensated heart failure in randomized clinical trials (11, 22, 36 ).
In our model of decompensated heart failure, the increase in ANF was significantly greater than that observed during pathologic hypertrophy. Interestingly, BNP levels during this state were significantly lower than in pathologic hypertrophy and closer to the normal level. This finding contrasts with the plasma BNP levels in patients that present with heart failure. However, our finding regarding BNP is supported by the fact that tissue mRNA BNP levels may not correlate well with plasma BNP levels, and that post-translational control may play a major role in the regulation of BNP gene expression in heart (52) . This might explain the effectiveness of Nesiritide ® during decompensated heart failure, despite high circulating plasma BNP levels. Of note, there are other studies showed that the mRNA level of BNP was not elevated at a compensatory hypertrophic stage, but only at a decompensated stage in Dahl saltsensitive rats (46, 56) . However, it would be difficult to make comparison with these papers since the mRNA level for "decompensated group of rats" were done after only 12 weeks of high salt diet (compare to 15-18 weeks in our study). At this stage, there was no deterioration in systolic cardiac function, which was comparable to our rats at 6 weeks of high salt diet (56) . In our study, ejection fraction was significantly depressed and the 16 rats were clinically in heart failure ( Table 2) , which is consistent with previously published data on these rat model during the transition to heart failure (21,25).
In conclusion, our study shows that there are distinct genetic regulations that appear to be specific to whether hypertrophic stimuli are physiologic or pathologic.
Although further studies are needed to confirm these findings, we believe this study provides comprehensive gene alterations as well as significantly altered pathways during various forms of cardiac hypertrophy. These differences may give insight into why the propensity for cardiac hypertrophy to progress to heart failure differs for different stimuli.
In addition, the molecular switching that may occur during the transition could be a key component of understanding the molecular mechanism of heart failure and finding therapeutic targets for the treatment of heart failure. 
